Recruiting

IMPACTIntegrative Chinese-Western Medicine Management for COPD with Comorbidities

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This observational study aims to monitor the annual rate of COPD exacerbations and the incidence of related comorbidities, such as hypertension, coronary artery disease, arrhythmia, heart failure, and diabetes, in individuals managed with a combination of Chinese and Western medicine.

What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Chronic Disease+5

+ Lung Diseases

+ Lung Diseases, Obstructive

From 40 to 80 Years
+26 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: February 2026
See protocol details

Summary

Principal SponsorBeijing Chao Yang Hospital
Study ContactZujin Luo, MD
Last updated: March 20, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 26, 2026

Actual date on which the first participant was enrolled.

COPD, or Chronic Obstructive Pulmonary Disease, is a common, long-term respiratory condition that often comes with other health issues. These additional conditions can worsen COPD symptoms, cause sudden flare-ups, lead to hospital stays, and contribute to the disease's progression over time. This study, called the IMPACT COPD Cohort in China, aims to create a real-world foundation for managing COPD and its related health issues using a combined approach of Chinese and Western medicine. The study focuses on individuals at high risk and those already diagnosed with related conditions, with the goal of improving long-term care, addressing current challenges, and meeting unmet needs for COPD management. Participants in this observational study will undergo regular clinical evaluations, including symptom assessments, questionnaires, lung function tests, imaging, and biomarker analysis. They will also use wearable devices to continuously monitor heart rate, blood pressure, activity levels, sleep patterns, and other physiological and behavioral measures. Additionally, the study will employ digital Traditional Chinese Medicine techniques, such as tongue, pulse, and facial diagnostics. The primary outcomes measured are the annual rate of COPD flare-ups and the occurrence of related conditions like high blood pressure, heart diseases, diabetes, among others.

Official TitleIntegrative Medicine Program for COPD With Comorbidity Management
NCT07382986
Principal SponsorBeijing Chao Yang Hospital
Study ContactZujin Luo, MD
Last updated: March 20, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

10000 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 40 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Chronic DiseaseLung DiseasesLung Diseases, ObstructivePathologic ProcessesRespiratory Tract DiseasesPathological Conditions, Signs and SymptomsDisease AttributesPulmonary Disease, Chronic Obstructive

Criteria

2 inclusion criteria required to participate
Age 40-80 years

Diagnosis of chronic obstructive pulmonary disease (COPD) according to the 2025 GOLD criteria

24 exclusion criteria prevent from participating
Acute exacerbation of COPD within the past 4 weeks

Presence of other pulmonary diseases causing chronic respiratory failure in addition to COPD, such as severe bronchiectasis, pneumoconiosis, post-tuberculosis destroyed lung, chest wall deformity, or neuromuscular disease

Cystic fibrosis or interstitial lung disease

Severe respiratory failure requiring long-term mechanical ventilation via tracheostomy

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 4 locations

Recruiting

Hebi Coal Industry Group General Hospital

Hebi, ChinaOpen Hebi Coal Industry Group General Hospital in Google Maps
Recruiting

Tongliao Second People's Hospital

Tongliao, China
Recruiting

Mianyang Third People's Hospital

Mianyang, China
Recruiting

The First Affiliated Hospital of Shihezi University

Shihezi, China
Recruiting
4 Study Centers